We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
Read MoreHide Full Article
Mesoblast Limited (MESO - Free Report) announced that the FDA has approved Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in children aged two months and older, including adolescents and teenagers.
Following the FDA nod, Ryoncil became the first and only mesenchymal stromal cell therapy to be approved for any indication in the United States.
Ryoncil is also the first FDA-approved therapy for pediatric SR-aGvHD, a life-threatening condition with high mortality rates.
Shares of MESO were up 40.4% in after-hours trading on Dec. 18. The stock has skyrocketed 456.8% in the year so far against the industry’s decline of 10.5%.
Image Source: Zacks Investment Research
More Updates on MESO's Ryoncil
The FDA approval was based on data from the phase III study which evaluated Ryoncil for treating children with SR-aGvHD.
Data from the same showed that out of 89% of children who had high severity grade C or grade D disease, 70% achieved an overall response by day 28 following treatment with Ryoncil, a measure that predicts survival in aGVHD.
Treatment with Ryoncil was not discontinued at any point of the study due to any laboratory abnormality in the given patient population.
Currently, there are no approved therapies in the United States for treating patients under 12 years of age suffering from aGvHD, which should provide Mesoblast with a significant market opportunity.
Ryoncil is also being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease.
Competition in the Target Market
Incyte Corporation’s (INCY - Free Report) lead drug, Jakafi, is approved for the treatment of SR-aGvHD in adult and pediatric patients aged 12 years and above in the United States. Jakafi is a first-in-class JAK1/JAK2 inhibitor.
Jakafi generated sales worth $2.02 billion in the first nine months of 2024. The drug has been witnessing a steady demand.
We note that Jakafi is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets.
INCY receives royalty revenues from NVS for the commercialization of Jakavi in ex-U.S. markets.
Jakafi is also approved for chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.
Incyte’s Jakafi was initially approved in the United States for treating adult patients with polycythemia vera (“PV”), who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of adult patients with intermediate or high-risk myelofibrosis (“MF”), including primary MF, post-PV MF and post-essential thrombocythemia MF.
MESO's Zacks Rank & Key Pick
Mesoblast currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. During the same time, estimates for 2025 loss per share have narrowed from $1.54 to 79 cents. Year to date, shares of SPRO have lost 32.3%.
SPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 94.42%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
Mesoblast Limited (MESO - Free Report) announced that the FDA has approved Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in children aged two months and older, including adolescents and teenagers.
Following the FDA nod, Ryoncil became the first and only mesenchymal stromal cell therapy to be approved for any indication in the United States.
Ryoncil is also the first FDA-approved therapy for pediatric SR-aGvHD, a life-threatening condition with high mortality rates.
Shares of MESO were up 40.4% in after-hours trading on Dec. 18. The stock has skyrocketed 456.8% in the year so far against the industry’s decline of 10.5%.
Image Source: Zacks Investment Research
More Updates on MESO's Ryoncil
The FDA approval was based on data from the phase III study which evaluated Ryoncil for treating children with SR-aGvHD.
Data from the same showed that out of 89% of children who had high severity grade C or grade D disease, 70% achieved an overall response by day 28 following treatment with Ryoncil, a measure that predicts survival in aGVHD.
Treatment with Ryoncil was not discontinued at any point of the study due to any laboratory abnormality in the given patient population.
Currently, there are no approved therapies in the United States for treating patients under 12 years of age suffering from aGvHD, which should provide Mesoblast with a significant market opportunity.
Ryoncil is also being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease.
Competition in the Target Market
Incyte Corporation’s (INCY - Free Report) lead drug, Jakafi, is approved for the treatment of SR-aGvHD in adult and pediatric patients aged 12 years and above in the United States. Jakafi is a first-in-class JAK1/JAK2 inhibitor.
Jakafi generated sales worth $2.02 billion in the first nine months of 2024. The drug has been witnessing a steady demand.
We note that Jakafi is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets.
INCY receives royalty revenues from NVS for the commercialization of Jakavi in ex-U.S. markets.
Jakafi is also approved for chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.
Incyte’s Jakafi was initially approved in the United States for treating adult patients with polycythemia vera (“PV”), who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of adult patients with intermediate or high-risk myelofibrosis (“MF”), including primary MF, post-PV MF and post-essential thrombocythemia MF.
MESO's Zacks Rank & Key Pick
Mesoblast currently carries a Zacks Rank #3 (Hold).
A better-ranked stock from the biotech sector is Spero Therapeutics, Inc. (SPRO - Free Report) , sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. During the same time, estimates for 2025 loss per share have narrowed from $1.54 to 79 cents. Year to date, shares of SPRO have lost 32.3%.
SPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 94.42%.